Free Trial

Haemonetics (HAE) Stock Forecast & Price Target

→ Check out WFC chart (From DTI) (Ad)
Free HAE Stock Alerts
$82.73
-0.45 (-0.54%)
(As of 06/28/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends

Haemonetics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings

Consensus Price Target

$109.50
32.36% Upside
High Forecast$125.00
Average Forecast$109.50
Low Forecast$94.00
TypeCurrent Forecast
7/1/23 to 6/30/24		1 Month Ago
6/1/23 to 5/31/24		3 Months Ago
4/2/23 to 4/1/24		1 Year Ago
7/1/22 to 7/1/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$109.50$108.67$104.67$103.17
Forecasted Upside32.36% Upside17.01% Upside28.02% Upside22.34% Upside

HAE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HAE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Haemonetics Stock vs. The Competition

TypeHaemoneticsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside32.36% Upside804.36% Upside11.50% Upside
News Sentiment RatingPositive News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/12/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Buy$112.00+34.32%
5/10/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetMarket Outperform ➝ Market Outperform$115.00 ➝ $125.00+31.58%
5/10/2024Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$105.00 ➝ $107.00+12.73%
10/2/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$90.00 ➝ $94.00+6.00%
2/8/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight$84.00 ➝ $88.00+2.97%
2/8/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$110.00 ➝ $115.00+39.28%
This TSLA short trade is on a nine win hot streak (Ad)

Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.

But I can promise that you’ll see all the details for yourself here.
11/8/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$88.00 ➝ $100.00+19.66%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:28 PM ET.

HAE Forecast - Frequently Asked Questions

What is Haemonetics's stock forecast and purchase recommendation?

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Haemonetics is $109.50, with a high forecast of $125.00 and a low forecast of $94.00. The consensus rating for Haemonetics stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for HAE. Learn more on HAE's analyst rating history.

Do Wall Street analysts like Haemonetics more than its competitors?

Analysts like Haemonetics more than other "medical" companies. The consensus rating score for Haemonetics is 2.75 while the average consensus rating score for "medical" companies is 2.71. Learn more on how HAE compares to other companies.

Is Haemonetics being upgraded by Wall Street analysts?

Over the previous 90 days, Haemonetics's stock had 1 upgrade by analysts.

Does Haemonetics's stock price have much upside?

According to analysts, Haemonetics's stock has a predicted upside of 21.00% based on their 12-month stock forecasts.

What analysts cover Haemonetics?

Haemonetics has been rated by research analysts at Barrington Research, JMP Securities, and Needham & Company LLC in the past 90 days.


Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:HAE) was last updated on 6/30/2024 by MarketBeat.com Staff

From Our Partners
Elon Musk: THIS will be bigger than Tesla
If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...
Paradigm Press | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
A Silent Invasion of America
The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...
The Freeport Society | Sponsored
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
Silver Expected for Extreme Price Action
Our newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...
Colonial Metals | Sponsored
Trump’s arrest is phase one
In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the...
Porter & Company | Sponsored
Where AI is REALLY Going Next
Buying Nvidia was a good idea – twenty years ago when I first recommended it (for up to 37,000% gains). But...
InvestorPlace | Sponsored
Who are Nvidia’s Silent Partners?
Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.
Weiss Ratings | Sponsored